

Please type a plus sign (+) inside this box → ☐

SEP 21 2001

Approved for use through 10/31/2002. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY OR
AUTHORIZATION OF AGENT**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Title	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
Group Art Unit	1647
Examiner Name	Turner, Sharon L.
Attorney Docket Number	15270J-004740US

I hereby appoint:

☒ Practitioners at Customer Number
OR

20350

Place Customer
Number Bar Code
Label here

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☐ Practitioners at Customer Number

☐ Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name	Neuralab Limited, by: Kevin Insley, Vice President
Signature	<i>Kevin Insley</i>
Date	August 31, 2001

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☒ *Total of 1 form is submitted.


Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for PA 3167222 v1

RECEIVED

OCT 01 2001

Please type a plus sign (+) inside this box → ☐

SEP 21 2001



PTO/SB/81 (02-01)

Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TECH CENTER 1600/2900

OCT 01 2001

RECEIVED

**POWER OF ATTORNEY OR
AUTHORIZATION OF AGENT**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Title	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
Group Art Unit	1647
Examiner Name	Turner, Sharon L.
Attorney Docket Number	15270J-004740US

I hereby appoint:

☐ Practitioners at Customer Number

OR

☒ Practitioner(s) named below:

Place Customer
Number Bar Code
Label here

Name	Registration Number
Nina M. Ashton	37,273
Jean M. Duvall	32,731
Lisabeth F. Murphy	31,547

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☐ Practitioners at Customer Number

<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country					
Telephone			Fax		

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name	Neuralab Limited, by: Kevin Insley, Vice President
Signature	
Date	AUGUST 31, 2001

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☒ *Total of 1 form is submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3165163 v1

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Dale B. Schenk

Application No./Patent No.: 09/322,289

Filed/Issue Date: May 28, 1999

Entitled: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

Neuralab Limited

, a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Dale B. Schenk

To : Elan Pharmaceuticals, Inc.

The document was recorded in the United States Patent and Trademark Office at Reel 010396, Frame 0683, or for which a copy thereof is attached.

2. From: Elan Pharmaceuticals, Inc.

To : Neuralab Limited

The document was recorded in the United States Patent and Trademark Office at Reel 010794, Frame 0926, or for which a copy thereof is attached.

3. From:

To :

The document was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

September 1, 2001

Date


Signature

Kevin Insley

Typed or printed name

Vice President

Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OCT 01 2001

TECH CENTER 1600/2900

RECEIVED

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This Application	Continuation of	09/322,289	05/28/99
09/322,289	Continuation-in-part of	09/201,430	11/30/98

Foreign Priority Information

Country::	Application number::	Filing Date::
-----------	----------------------	---------------

Assignee Information

Assignee Name::	Neuralab Limited
Street of mailing address::	102 St. James Court
City of mailing address::	Flatts, Smiths
State or Province of mailing address::	
Country of mailing address::	Bermuda
Postal or Zip Code of mailing address::	FL 04